Considering the association between adjuvant chemotherapy and PROK1 expression, even among the patients who received adjuvant chemotherapy, the PROK1-positive group showed a lower 5-year cancer-related survival rate than the negative group (61.5% [95% CI 30.8‐81.8] vs. 92% [95% CI 80.1‐96.9], HR 2.27 [95% CI 1.30‐3.94], P = 0.001, Fig. 6A). Here, PROK1 is linked to cancer.